UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2].

UC-1V150 (0.01-10 μM, 24 hour) can stimulate the release of IL-6 and IL-2 cytokines effectively in bone-marrow-derived macrophages [1]. UC-1V150 (1 μg/mL, 48 hours) can increase the expression of FcγRIIA and FcγRIII while inducing an approximately 1.5-fold increase in macrophage phagocytosis index of target cells in hman monocyte-derived macrophages (hMDM) [2].

UC-1V150 (intravenous injection, 0.38-38 nM, once, 2 hours) effectively induces release of serum cytokines within a certain concentration range in female C57BL/6 mice (5-6 weeks of age) [1]. Animal Model: Female C57BL/6 mice (5–6 weeks of age) [1] Dosage: 0.38-38 nM Administration: Intravenous injection; once; 2 hours Result: Induced serum cytokine IL-6 levels about 0.1 ng/mL and IL-2 levels about 1.5 ng/mL at the concentration of 38 nM.